Atyr_Logo.png
aTyr Pharma and FUJIFILM Diosynth Biotechnologies Announce Manufacturing Agreement for aTyr’s Lead Therapeutic Candidate ATYR1923
November 30, 2021 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Atyr_Logo.png
aTyr Pharma to Present at Upcoming Investor Conferences in November
November 12, 2021 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Atyr_Logo.png
aTyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update
November 10, 2021 16:00 ET | aTyr Pharma, Inc.
Positive results reported from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis provided proof-of-concept for ATYR1923 and validation for tRNA synthetase biology platform and NRP2...
Atyr_Logo.png
aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2021 Financial Results
November 03, 2021 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Atyr_Logo.png
aTyr Pharma to Participate in Piper Sandler Investor Lung Day
October 11, 2021 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Atyr_Logo.png
aTyr Pharma Announces Appointment of Robert W. Ashworth, PhD, as Vice President of Regulatory Affairs
October 06, 2021 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Atyr_Logo.png
aTyr Pharma Announces Closing of $86.3 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 20, 2021 16:07 ET | aTyr Pharma, Inc.
SAN DIEGO, Sept. 20, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on...
Atyr_Logo.png
aTyr Pharma to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
September 16, 2021 16:01 ET | aTyr Pharma, Inc.
SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Atyr_Logo.png
aTyr Pharma Announces Proposed Public Offering of Common Stock
September 15, 2021 16:01 ET | aTyr Pharma, Inc.
SAN DIEGO, Sept. 15, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on...
Atyr_Logo.png
aTyr Pharma and its Hong Kong Subsidiary, Pangu BioPharma, Announce Positive Data from a Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response of ATYR1923 in Pulmonary Sarcoidosis
September 13, 2021 07:30 ET | aTyr Pharma, Inc.
Pangu’s basic and translational research in tRNA synthetase biology, conducted in collaboration with the Hong Kong University of Science and Technology, contributed to successful clinical...